London - A urine test for pancreatic cancer could boost survival rates to 60 percent, scientists believe.
The test, developed by researchers at Queen Mary University of London, has reached the final stage of validation before being developed for use with patients.
Once approved it will be the world’s first quick and accurate test to diagnose pancreatic cancer in the early stages, which could revolutionise survival chances.
Pancreatic cancer is also one of the most deadly – one in four patients die within a month of diagnosis.
Only 3% survive for five years, compared to 87% for breast cancer and 98% for testicular cancer.